naronapride
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2005 (NCT01094821)
Timeline
Indications
Mechanism of action
- Serotonin 4 (5-HT4) receptorAGONIST
HTR4 agonist
two Ph2 studies terminated, no reason given.
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCCCC(=O)O[C@H]2CN3CCC2CC3)C[C@@H]1OC- Mol. weight
- 537.1 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2103858 ↗
Also known as
- ati7505
- ati 7505
- ati 7505
- ati 7505
- ati-7505
- ati-7505
- ati-7505
- ati-7505
- naronapride
- naronapride
- naronapride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05621811 | Phase 2 | Nov 30, 2022 | Dr. Falk Pharma GmbH |
| NCT00630370 | Phase 2 | Feb 1, 2008 | ARYx Therapeutics, Procter and Gamble |
| NCT00501241 | Phase 2 | Jul 1, 2007 | Procter and Gamble |
| NCT01094821 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2005 | ARYx Therapeutics, Mayo Clinic |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ARYx Therapeutics | For profit | 2 | 0 | 1 | 2005 |
| Procter and Gamble | For profit | 2 | 2 | 1 | 2007 |
| Dr. Falk Pharma GmbH | For profit | 1 | 1 | 1 | 2022 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2005 |
4 organizations
Page 1 / 1